Compare · MEDP vs OABI
MEDP vs OABI
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $15.36B, about 50.0x OABI ($307.3M).
- MEDP has been more active in the news (5 items in the past 4 weeks vs 4 for OABI).
- MEDP has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- Medpace Holdings Inc.
- OmniAb Inc.
- Price
- -
- -
- Market cap
- $15.36B
- $307.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 5
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
Latest OABI
- OmniAb to Report Second Quarter 2026 Financial Results on August 6
- SEC Form 3 filed by new insider Nwachuku Amechi Ekeke
- OmniAb Inc. filed SEC Form 8-K: Leadership Update
- OmniAb Names Amechi Nwachuku Chief Operating Officer
- Director Bertozzi Carolyn R converted options into 20,000 shares, increasing direct ownership by 21% to 113,308 units (SEC Form 4)
- Director Cochran Jennifer R. converted options into 20,000 shares, increasing direct ownership by 12% to 185,274 units (SEC Form 4)
- Director Crouse Steven C. converted options into 20,000 shares, increasing direct ownership by 150% to 33,333 units (SEC Form 4)
- Director Gotwals Philip J converted options into 20,000 shares, increasing direct ownership by 150% to 33,333 units (SEC Form 4)
- Director Higgins John L converted options into 20,000 shares, increasing direct ownership by 0.68% to 2,962,320 units (SEC Form 4)
- Director Love Steven converted options into 20,000 shares, increasing direct ownership by 28% to 91,666 units (SEC Form 4)